Article Text

Novel treatment (new drug/intervention; established drug/procedure in new situation)
Combination treatment of intravenous immunoglobulin and cultivated oral mucosal epithelial transplantation for ocular cicatricial pemphigoid
  1. Y Uchino1,
  2. M Uchino2,
  3. J Shimazaki1
  1. 1
    Tokyo Dental College, Ophthalmology, 5-11-13 Sugano, Ichikawa, Tokyo, Chiba 272-8513, Japan
  2. 2
    Ryogoku Eye Clinic, 4-33-12 Ryogoku, Sumida-ku, Tokyo, 130–0026, Japan
  1. uchino{at}2001.jukuin.keio.ac.jp

Summary

Ocular cicatricial pemphigoid (OCP) is a progressive cicatrising autoimmune disease affecting the skin and mucous membranes, including ocular surface epithelia. Although systemic immunosuppression is advocated, both progression of ocular surface inflammation and systemic side effects remain a problem. For the treatment of an active OCP, both control of autoimmune reaction and ocular surface reconstruction are necessary. We believe that the combination of intravenous immunoglobulin (IVIg) and cultivated oral mucosal epithelial transplantation (COMET) is a powerful treatment modality while minimising the risk of postoperative consequences inevitably associated with immunosuppression. A patient with OCP successfully treated by a combination of IVIg and COMET is described here.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.